USE OF THE PROTEIN KINASE C INHIBITOR TAMOXIFEN FOR THE TREATMENT OF BIPOLAR DISORDER

摘要

Bipolar subjects with manic/mixed episode were randomly assigned to receive either tamoxifen (80mg/day) or identical placebo tablets in 1:1 ratio for three weeks. At the end of three weeks of trial tamoxifen treatment has been shown to have strong anti-manic properties. Protein kinase C inhibition seems to be one of the direct targets of lithium and valproate, The existing effective treatments in bipolar disorder/mania. These findings may lead to delineation of the underlying pathophysiology of bipolar disorder and development of novel therapeutics.